Navigation Links
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Date:1/13/2009

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care-

NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer.

In the study, patients receiving XELOX lived for a median of 19.0 months, while patients receiving FOLFOX-4 lived for a median of 18.5 months. The consistency of these results were also further demonstrated in a subset population from the original two-arm part of the study (XELOX v. FOLFOX). These data will be presented later this week at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, Calif.

"These compelling data validate previous studies showing that XELOX is comparable to FOLFOX-4 for the treatment of advanced colorectal cancer, while providing the added flexibility of the proven oral component Xeloda," said Edward Chu, M.D., chief of medical oncology, Yale Cancer Center. "Together, these studies confirm the value and importance of combination therapy with oral Xeloda for the thousands of patients with this insidious disease."

Colorectal cancer is the third most common cancer in the United States. The American Cancer Society estimated that in 2008 more than 148,000 people in the U.S. would be diagnosed and about 50,000 people would die from the disease. (1)

Previous data reported from the NO16966 study showed that XELOX is comparable to FOLFOX-4 in terms of progression-free survival, and the addition of Avastin to chemotherapy (FOLFOX-4 and XELOX) significantly improved progression-free survival by investigator assessment compared to chemotherapy alone. Fu
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
2. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
3. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
8. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Minimally Invasive Devices Inc. ... device company, announced today that Mitsubishi Corporation has formally ... visualization system in Japan . MID ... Japan in the second half ... exclusive distributor for Karl Storz GMBH & Co. (endoscopic ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp ... A funding round led by Walden Riverwood Ventures ... the development of Atonarp,s Smart Spectrometer technology platform, ... The company has targeted the oil & gas ... "We are excited to partner with Atonarp ...
(Date:8/19/2014)...  Boehringer Ingelheim today announced that the U.S. ... the New Drug Application (NDA) for the fixed-dose ... the Respimat ® inhaler for the proposed ... obstruction in patients with chronic obstructive pulmonary disease ... olodaterol FDC will not be indicated to treat ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
(Date:8/19/2014)... 2014 Recently, Skmen.com, an outstanding company in ... bohemian dresses . In addition to this, the company ... Now, all of them are available at low rates, up ... product design and quality. Its beautiful bohemian outfits are available ... many others. Owing to its top quality clothes, reasonable prices ...
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... has recently compared many popular hosting suppliers and announced ... recommended companies for webmasters who want to buy high ... an affordable price. , Both GoDaddy and iPage ... the lowest upfront costs (including some Joomla hosting products ... of options. , GoDaddy is a famous supplier ...
(Date:8/19/2014)... 19, 2014 Grande Naturals, LLC ... winner of the 2014 Independent Cosmetics Manufacturers & ... first place position in “Product Innovation; Product Color ... which also includes a lash enhancement serum, GrandeLINER™. ... lash-boosting technology. , This all-new eyeliner ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
Breaking Medicine News(10 mins):Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... June 17 NeoMend, Inc. today announced,that its ... from the U.S. Food and Drug Administration,s (FDA) ... panel,s recommendation will be considered by the FDA ... (PMA) for ProGEL. The,panel,s recommendation for FDA approval ...
... BOSTON--Patients diagnosed with colon cancer who had abundant vitamin D ... follow-up period than those who were deficient in the vitamin, ... Institute. , The findings of the study -- the first ... patients -- merit further research, but it is too early ...
... Access to Personal ... Enrolls Nearly 1,000 Police Officers in MedeFile System During National ... ... Board: MDFI), a company specializing in,portable electronic medical records management solutions, today announced,that ...
... -- Research findings and innovative approaches offer the promise ... adults living with type 1 diabetes, according to researchers ... Forum in Washington D.C. , Type 1 diabetes is ... insulin-producing beta cells in the pancreas. It renders ...
... June 18 A CI head once noted that,"Competitive ... but the only,time you realize you need it is ... marketing space, most companies need competitive,intelligence to effectively deal ... insights are lacking that people begin to realize how,critical ...
... 18 Sunrise Senior Living,Inc. (NYSE: SRZ ), ... will present at the 2008 Jefferies 2nd Annual,Healthcare Conference ... 1:30 p.m.,Eastern Time. Sunrise will Web cast the presentation ... http://www.sunriseseniorliving.com ). A replay of the Web cast will ...
Cached Medicine News:Health News:NeoMend Receives FDA Panel's Recommendation for Approval of ProGEL(TM) Surgical Sealant 2Health News:Study links vitamin D to colon cancer survival 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 3Health News:MedeFile International Teams with Newark Fraternal Order of Police 4Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: